LILRB2(BMS-986406 Biosimilar Antibody)重組單克隆抗體是一款專為科研用途開(kāi)發(fā)的生物試劑，其靶點(diǎn)為白細(xì)胞免疫球蛋白樣受體B2（LILRB2）。該抗體通過(guò)基因工程技術(shù)在哺乳動(dòng)物細(xì)胞中表達(dá)，具有高純度、高特異性和高親和力的特點(diǎn)，為免疫調(diào)控機(jī)制研究提供了可靠工具。 LILRB2作為免疫球蛋白超家族成員，主要表達(dá)于單核細(xì)胞、巨噬細(xì)胞和樹(shù)突狀細(xì)胞等免疫細(xì)胞表面，通過(guò)與MHC I類分子等配體結(jié)合，傳遞抑制性信號(hào)，負(fù)向調(diào)控免疫應(yīng)答。本產(chǎn)品可特異性識(shí)別并結(jié)合LILRB2胞外結(jié)構(gòu)域，阻斷其與配體的相互作用，進(jìn)而用于探究該受體在腫瘤免疫逃逸、自身免疫性疾病及感染性疾病中的功能機(jī)制。 該抗體經(jīng)過(guò)嚴(yán)格的質(zhì)量控制，包括SDS-PAGE純度分析、SEC-HPLC聚合體檢測(cè)、ELISA結(jié)合活性驗(yàn)證及表面結(jié)合實(shí)驗(yàn)等，確保批次間穩(wěn)定性和實(shí)驗(yàn)結(jié)果的可重復(fù)性。其適用范圍涵蓋及體外功能實(shí)驗(yàn)等多種研究場(chǎng)景，為深入解析LILRB2介導(dǎo)的信號(hào)通路及其在疾病發(fā)生發(fā)展中的作用提供有力支持。 作為科研用試劑，本產(chǎn)品僅用于實(shí)驗(yàn)室研究，不可用于診斷或治療用途。通過(guò)特異性靶向LILRB2，研究人員可進(jìn)一步揭示免疫檢查點(diǎn)調(diào)控網(wǎng)絡(luò)，為開(kāi)發(fā)新型免疫治療策略提供理論基礎(chǔ)和實(shí)驗(yàn)依據(jù)。

Q8N423

BMS986406 research-grade biosimilar; BMS 986406 research-grade biosimilar; BMS-986406 research-grade biosimilar ;LILRB2 antibody; ILT4 antibody; LIR2 antibody; MIR10 antibody; Leukocyte immunoglobulin-like receptor subfamily B member 2 antibody; LIR-2 antibody; Leukocyte immunoglobulin-like receptor 2 antibody; CD85 antigen-like family member D antibody; Immunoglobulin-like transcript 4 antibody; ILT-4 antibody; Monocyte/macrophage immunoglobulin-like receptor 10 antibody; MIR-10 antibody; CD antigen CD85d antibody

Human

Recombinant Human LILRB2 protein

Homo sapiens (Human)

Non-conjugated

Monoclonal

It differs from different batches. Please contact us to confirm it.

0.01M PBS，pH7.4

Liquid

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

3-4 weeks

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.